• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.07% Nasdaq Up0.32%

    Innovus Pharmaceuticals, Inc. (INNV)

    -Other OTC
    0.15 Up 0.00(2.07%) Aug 28, 3:57PM EDT
    |Pre-Market : NaN
    Add to Portfolio
    ProfileGet Profile for:
    Innovus Pharmaceuticals, Inc.
    9171 Towne Centre Drive
    Suite 440
    San Diego, CA 92122
    United States - Map
    Phone: 858-964-5123
    Fax: 858-249-7879
    Website: http://www.innovuspharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:3

    Business Summary 

    Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription pharmaceutical and consumer health products in the United States and internationally. The company’s products include Zestra, a non-medicated, patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity low osmolality water-based lubricant; and Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health. It has an agreement with Laboratorios Q Pharma to distribute and commercialize Androferti, a natural supplement that supports male reproductive health and sperm quality; and develops Fluticare, a nasal spray in the form of fluticasone propionate, which is in FDA approval stage. The company markets its products directly or through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Innovus Pharmaceuticals, Inc.

    Key Executives 
    Dr. Bassam B. Damaj Ph.D., 47
    Chief Exec. Officer, Pres and Director
    Mr. Reuven Rubinson CPA,
    VP of Fin.
    Mr. Randy J. Berholtz Esq., J.D., 53
    Exec. VP, Compliance Officer, Gen. Counsel and Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders